Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse.

Details

Language :

English

ISSN :

1569-8041

Database :

MEDLINE

Journal :

Annals of oncology : official journal of the European Society for Medical Oncology

Publication Type :

Editorial & Opinion

Accession number :

39443188

Full Text :

https://doi.org/10.1016/j.annonc.2024.09.018